Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| folate inhibitors; inhibits purine/pyrimidine syn shunts to adenine which is antiinflammatory |
|
|
Term
| frequency of sulfasalazine dose" |
|
Definition
|
|
Term
|
Definition
| broken down by bacteria in the colon to ASA and Sulfa SAS; SAS absorbed ASA excreted |
|
|
Term
| contraindications to sulfasalazine: |
|
Definition
| hypersensativity to ASA or Sulfa |
|
|
Term
| onset of action for sulfasalazine: |
|
Definition
|
|
Term
| still detected after 2 years: |
|
Definition
|
|
Term
| freq of dose for leflunomide: |
|
Definition
|
|
Term
|
Definition
|
|
Term
| onset of action for leflunomide: |
|
Definition
|
|
Term
| traditional DMARD that is highly protein bound |
|
Definition
|
|
Term
|
Definition
|
|
Term
| freq of dose in hydroxychloroquine: |
|
Definition
|
|
Term
| onset of action for hydroxychloroquine |
|
Definition
|
|
Term
|
Definition
1. MTX
2. Sulfasalozine
3. Leflunamide
4. hydroxychloroquine |
|
|
Term
| suffixes for biologic DMARDs |
|
Definition
|
|
Term
| which biologic DMARDs are IV admin?4 |
|
Definition
1. inflixamab
2. rituximab
3. abatacept
4. tolcilizumab |
|
|
Term
| 2 biologics that are chimeric: |
|
Definition
1. rituximab
2. infliximab |
|
|
Term
| IL-1 receptor antagonist: |
|
Definition
|
|
Term
| binds to CD-20 on Bcells: |
|
Definition
|
|
Term
| inhibits T cell activation: |
|
Definition
|
|
Term
| IL-6 receptor antagonist: |
|
Definition
|
|
Term
| indication for minocycline/MOA: |
|
Definition
1 used in low dz activity
2. used in pts w better prognosis
3. MOA: inhibits collagenase activity |
|
|
Term
| biologic DMARD that is from hamster: |
|
Definition
|
|
Term
| biologic that is from mice: |
|
Definition
|
|
